Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

Colorectal cancer (CRC) is a highly malignant disease that readily metastasizes to vital organs. Many strategies have been employed for clinical CRC therapy.

showed that aspirin use in patients with PIK3CA-mutated colorectal cancer reduced recurrence risk by 50% compared with placebo. 1 “This is the first trial to show that mutations in this specific ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations ...

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation ...

Survival outcomes for right- versus left-sided colon cancer and rectal cancer in patients receiving regorafenib and/or trifluridine/tipiracil for refractory metastatic colorectal cancer: Findings from ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the ...

“The old adage ‘take two aspirin and call me in the morning’ may now find a new meaning. A simple intervention of low-dose aspirin reduces the risk of colorectal cancer recurrence for patients with ...

Adjuvant treatment with 160 mg aspirin daily for three years cuts recurrence rates in patients with colorectal cancer.

rectal cancer (RC). Hazard ratios (HR), sensitivity, and specificity, with 95% confidence intervals (95% CI), for the association of ctDNA status with recurrence-free survival (RFS) at the ...